Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
01 août 2023 08h30 HE
|
Qualigen Therapeutics, Inc.
Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need...
Qualigen Therapeutics Divests FastPack® Diagnostics Business
24 juil. 2023 08h15 HE
|
Qualigen Therapeutics, Inc.
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 ...
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
16 mai 2023 08h00 HE
|
Qualigen Therapeutics, Inc.
Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused...
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
02 mai 2023 08h15 HE
|
Qualigen Therapeutics, Inc.
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
18 avr. 2023 08h45 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
18 avr. 2023 07h30 HE
|
Qualigen Therapeutics, Inc.
In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen”...
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
21 mars 2023 08h35 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
15 mars 2023 09h05 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
09 mars 2023 08h30 HE
|
Qualigen Therapeutics, Inc.
Data demonstrates potential anti-RAS activity with Qualigen’s novel RAS small molecule in both pancreatic and breast cancer in vivo models CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) --...
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
08 mars 2023 08h05 HE
|
Qualigen Therapeutics, Inc.
S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the...